摘要
阿柏西普是一种与血管内皮生长因子-A、B及胎盘生长因子特异性结合的人源化重组融合蛋白,其通过降低血管内皮通透性进而抑制新生血管生成,在病理性血管形成过程中扮演重要角色。近年来,该药在医学领域的应用范围不断扩大,在结直肠癌、卵巢癌、糖尿病性黄斑水肿、老年性黄斑变性、视网膜静脉阻塞及早产儿视网膜病变等治疗中均被广泛应用,并取得较好效果。本文旨在综述阿柏西普的药理学特点及其在眼科疾病中的应用现状、治疗优势,为后续药物研究和临床应用提供更多的治疗策略。
Aflibercept is a humanized recombinant fusion protein that specifically binds to vascular endothelial growth factor-A,B and placental growth factor.It plays an important role in pathological angiogenesis by reducing vascular endothelial permeability and thereby inhibiting neovascularization.In recent years,Aflibercept has been widely used in the treatment of colorectal cancer,ovarian cancer,diabetic macular edema,age-related macular degeneration,retinal vein occlusion and retinopathy of prematurity,and achieved good results.The article has reviewed the pharmacological characteristics of Aflibercept and its current application status and therapeutic advantages in ocular diseases,so as to provide more treatment strategies for subsequent drug research and clinical drug selection.
作者
张国明
田娅
ZHANG Guoming;TIAN Ya(Shenzhen Eye Hospital,the Second Clinical College of Jinan University Shenzhen Eye Hospital,the School of Optometry&Ophthalmology of Shenzhen University,Shenzhen 518040,Guangdong Province,China;Guizhou Medical University,Guiyang 550004,Guizhou Province,China)
出处
《眼科新进展》
CAS
北大核心
2020年第1期1-5,共5页
Recent Advances in Ophthalmology
基金
深圳市学科布局项目(编号:JCYJ20170817112542555)
关键词
阿柏西普
血管内皮生长因子
眼科
Aflibercept
vascular endothelial growth factor
ophthalmology
